In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) yesterday and set a price ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

The MSSG solidarity mechanism enables medicine sharing between EU states, with companies now required to report on drug ...